EcoDrugPlus

Ret Proto-Oncogene Receptor Tyrosine Kinase

Ensembl ID : ENSEEEG00000017064
Gene Symbol: RET
2 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSEEEG00000022733
Gene Symbol: RARB
4 Cross references
394 Possible Orthologues:

Retinoic Acid Receptor Gamma A

Ensembl ID : ENSEEEG00000019600
Gene Symbol: RARGA
4 Cross references
326 Possible Orthologues:

Retinoic Acid Receptor Gamma-A-Like

Ensembl ID : ENSEEEG00000015528
Gene Symbol: LOC113572452
4 Cross references
363 Possible Orthologues:

Retinoid X Receptor, Alpha B

Ensembl ID : ENSEEEG00000024157
Gene Symbol: RXRAB
4 Cross references
223 Possible Orthologues:

Retinoid X Receptor, Beta B

Ensembl ID : ENSEEEG00000013430
Gene Symbol: RXRBB
4 Cross references
215 Possible Orthologues:

Rho-Associated, Coiled-Coil Containing Protein Kinase 2a

Ensembl ID : ENSEEEG00000022979
Gene Symbol: ROCK2A
4 Cross references
216 Possible Orthologues:

Rho-Associated, Coiled-Coil Containing Protein Kinase 2b

Ensembl ID : ENSEEEG00000020786
Gene Symbol: ROCK2B
2 Cross references
214 Possible Orthologues:

Ribosomal Protein L10

Ensembl ID : ENSEEEG00000006045
Gene Symbol: RPL10
4 Cross references
408 Possible Orthologues:

Ribosomal Protein L10a

Ensembl ID : ENSEEEG00000007214
Gene Symbol: RPL10A
4 Cross references
381 Possible Orthologues:

Ribosomal Protein L11

Ensembl ID : ENSEEEG00000008901
Gene Symbol: RPL11
2 Cross references
288 Possible Orthologues:

Ribosomal Protein L12

Ensembl ID : ENSEEEG00000015168
Gene Symbol: RPL12
4 Cross references
490 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).